Transition Metal-based Anticancer Drugs Targeting Nucleic Acids: A Tandem Mass Spectrometric Investigation

Chimia (Aarau). 2017 Mar 29;71(3):120-123. doi: 10.2533/chimia.2017.120.

Abstract

The search for effective drugs against cisplatin-resistant tumors resulted in a large number of organometallic compounds that are evaluated for their antiproliferative activity. Among the most promising candidates are bent metallocenes based on various transition metal ions and ligands. The elucidation of structural features and the characterization of the interaction of a drug candidate with its target require accurate and sensitive analytical tools. Tandem mass spectrometry is applied to the investigation of the adduct sites and binding patterns of metallodrugs bound to single-stranded oligonucleotides and higher-order nucleic acids. Results reveal the binding specificities of the different metallodrugs and demonstrate the influence they exert on the dissociation pathways of the adducts in the gas-phase.

MeSH terms

  • Antineoplastic Agents / analysis
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Cisplatin / chemistry
  • DNA Adducts / chemistry
  • Humans
  • Metallocenes / chemistry
  • Molecular Targeted Therapy
  • Nucleic Acids / chemistry*
  • Oligonucleotides / chemistry
  • Organometallic Compounds / analysis
  • Organometallic Compounds / chemistry*
  • Organometallic Compounds / pharmacology
  • Software
  • Tandem Mass Spectrometry / methods*
  • Transition Elements

Substances

  • Antineoplastic Agents
  • DNA Adducts
  • Metallocenes
  • Nucleic Acids
  • Oligonucleotides
  • Organometallic Compounds
  • Transition Elements
  • Cisplatin